Drug profile · INN
glucagon hydrochloride
GLUCAGEN HYPOKIT
glucagon hydrochloride (GLUCAGEN HYPOKIT) is a glucagon receptor agonist. Associated with NovoThirteen. Route of administration: intramuscular, intravenous, subcutaneous. Current US regulatory status: approved.
Drug details — glucagon hydrochloride
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
- Patents
- 20
- Programs
- 19
- Data quality
- 0.84
Quick answer
glucagon hydrochloride (GLUCAGEN HYPOKIT) is a glucagon receptor agonist. Associated with NovoThirteen. Route of administration: intramuscular, intravenous, subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucagon receptor agonist
Primary target: Glucagon receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
WO 2025252715
AGONISTE DOUBLE DU RÉCEPTEUR DU GLP-1 ET DU GLUCAGON POUR LE TRAITEMENT DE LA MASH ET DE LA CIRRHOSE
granted -
US 12421317
Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies
granted -
US 12370241
Nasal powder formulation for treatment of hypoglycemia
granted -
US 12269889
Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels
granted -
US 12208071
Glucagon receptor antagonists
granted -
US 12139546
Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
granted -
US 12090193
Glucagon-like peptide 1 receptor agonists and uses thereof
granted -
US 11951176
Stabilization of glucagon by trehalose glycopolymer nanogels
granted -
US 11884736
Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)
granted -
US 11779633
Glucagon-like peptide 1 receptor agonists and uses thereof
granted -
US 11708416
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
granted -
US 11590205
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
granted -
US 11498970
Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels
granted -
US 11045522
Glucagon-like peptide 1 receptor agonists and uses thereof
granted -
US 10995146
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
granted -
US 10640566
Nucleic acid molecules encoding antibodies to the human glucagon receptor
granted -
US 10233250
Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels
granted -
US 9687527
Stable glucagon formulations for the treatment of hypoglycemia
granted -
US 9657099
Anti-glucagon antibodies
granted -
US 9649364
Methods for producing stable therapeutic formulations in aprotic polar solvents
granted
Frequently asked questions
What is glucagon hydrochloride?
glucagon hydrochloride (GLUCAGEN HYPOKIT) is a glucagon receptor agonist. Associated with NovoThirteen. Route of administration: intramuscular, intravenous, subcutaneous. Current US regulatory status: approved.
What is the brand name for glucagon hydrochloride?
GLUCAGEN HYPOKIT is a marketed brand name for glucagon hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of glucagon hydrochloride?
glucagon hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.